| Literature DB >> 27106405 |
Nathalie L Albert1, Michael Weller1, Bogdana Suchorska1, Norbert Galldiks1, Riccardo Soffietti1, Michelle M Kim1, Christian la Fougère1, Whitney Pope1, Ian Law1, Javier Arbizu1, Marc C Chamberlain1, Michael Vogelbaum1, Ben M Ellingson1, Joerg C Tonn2.
Abstract
This guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose ((18)F-FDG) and amino acid tracers ((11)C-MET, (18)F-FET, and (18)F-FDOPA). An increasing number of studies have been published on PET imaging in the setting of diagnosis, biopsy, and resection as well radiotherapy planning, treatment monitoring, and response assessment. Recommendations are based on evidence generated from studies which validated PET findings by histology or clinical course. This guideline emphasizes the clinical value of PET imaging with superiority of amino acid PET over glucose PET and provides a framework for the use of PET to assist in the management of patients with gliomas.Entities:
Keywords: PET imaging; amino acid PET; glioma; guideline; recommendations
Mesh:
Substances:
Year: 2016 PMID: 27106405 PMCID: PMC4999003 DOI: 10.1093/neuonc/now058
Source DB: PubMed Journal: Neuro Oncol ISSN: 1522-8517 Impact factor: 12.300